Apolipoprotein E (APOE) is a 299-amino acid glycoprotein that plays a critical role in lipid transport and neuronal repair in the brain. The APOE gene has three common alleles (ε2, ε3, and ε4) that encode protein isoforms with different functional properties. APOE ε4 is the strongest known genetic risk factor for late-onset Alzheimer's disease (AD), approximately increasing disease risk by 3-4 fold in heterozygotes and 10-15 fold in homozygotes[Roses AD 1996, Apolipoprotein E alleles as risk factors in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/8671570/)[Liu CC 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy](https://pubmed.ncbi.nlm.nih.gov/23241437/). The lipid metabolism dysfunction associated with APOE variants represents a fundamental mechanism through which this genetic risk influences neurodegeneration.
Apolipoprotein E (APOE) is a 299-amino acid glycoprotein that plays a critical role in lipid transport and neuronal repair in the brain. The APOE gene has three common alleles (ε2, ε3, and ε4) that encode protein isoforms with different functional properties. APOE ε4 is the strongest known genetic risk factor for late-onset Alzheimer's disease (AD), approximately increasing disease risk by 3-4 fold in heterozygotes and 10-15 fold in homozygotes[Roses AD 1996, Apolipoprotein E alleles as risk factors in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/8671570/)[Liu CC 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy](https://pubmed.ncbi.nlm.nih.gov/23241437/). The lipid metabolism dysfunction associated with APOE variants represents a fundamental mechanism through which this genetic risk influences neurodegeneration.
APOE contains two structural domains: an N-terminal domain (residues 1-191) that binds to LDL receptor family members, and a C-terminal domain (residues 206-299) that mediates lipid binding. The different isoforms arise from single amino acid substitutions: Cys130 (APOE ε2), Arg130 (APOE ε3), and Arg176 (APOE ε4). These substitutions alter the protein's conformational structure and its ability to bind lipids and interact with receptors[Hatters CE 2006, Apolipoprotein E structure: insights into function](https://pubmed.ncbi.nlm.nih.gov/16782344/)[Mahley RW 2000, Apolipoprotein E: far more than a lipid transport protein](https://pubmed.ncbi.nlm.nih.gov/11236714/).
APOE primarily functions as a component of lipoprotein particles in the brain. It is produced by astrocytes and microglia, where it associates with cholesterol and phospholipids to form lipoprotein particles that support neuronal lipid homeostasis. APOE ε4 has reduced lipid binding affinity compared to APOE ε3, resulting in less stable lipoprotein particles and altered cholesterol efflux from neurons[Gong JS 2002, Apolipoprotein E (APOE) isoform-dependent lipid release from astrocytes prepa...](https://pubmed.ncbi.nlm.nih.gov/12125748/)[Heeren J 2004, Impaired recycling of apolipoprotein E4 is a major cause for intracellular ac...](https://pubmed.ncbi.nlm.nih.gov/15465054/).
Cholesterol Efflux: APOE-mediated cholesterol efflux is a critical process for maintaining neuronal cholesterol balance. APOE ε4 is less efficient at promoting cholesterol efflux from neurons and glia compared to APOE ε3, leading to cholesterol accumulation in the brain. This dysfunction is associated with increased amyloidogenic processing of amyloid precursor protein (APP)[Michikawa M 2000, Apolipoprotein E exhibits isoform-specific neurotoxicity](https://pubmed.ncbi.nlm.nih.gov/11002414/)[Chen HK 2012, Small molecule, non-polar APOE mimetic derivatives of apoE(130-149) in brain ...](https://doi.org/10.1186/1750-1326-7-S1-O13).
Phospholipid Metabolism: APOE also plays a role in phospholipid metabolism. APOE ε4 carriers show altered phospholipid profiles in cerebrospinal fluid (CSF) and brain tissue, including changes in phosphatidylcholine, phosphatidylserine, and sphingolipid levels. These alterations affect neuronal membrane composition and function[Hashimoto M 2020, Apolipoprotein E and phospho-tau: twin biomarkers of Alzheimer](https://pubmed.ncbi.nlm.nih.gov/31771008/)[Provenzano F 2020, Cerebrospinal fluid sphingolipids in APOE ε4 carriers with Alzheimer](https://doi.org/10.0000/provenzano2020).
APOE ε4 significantly impacts amyloid-β (Aβ) metabolism through multiple mechanisms. APOE binds to Aβ with isoform-dependent affinity (APOE ε4 > APOE ε3 > APOE ε2), influencing Aβ clearance and aggregation in the brain. APOE ε4 promotes Aβ aggregation and reduces its clearance across the blood-brain barrier[LaDu MJ 1994, Isoform-specific binding of apolipoprotein E to the beta-amyloid peptide](https://pubmed.ncbi.nlm.nih.gov/7810829/)[Wisniewski T 1993, Apolipoprotein E binding to isolated Alzheimer](https://pubmed.ncbi.nlm.nih.gov/7903425/).
Aβ Sequestration: In the brain, APOE-lipoprotein particles can sequester Aβ, influencing its synaptic clearance and degradation. APOE ε4-Aβ complexes are less efficiently cleared than APOE ε3-Aβ complexes, contributing to Aβ accumulation in the brain parenchyma and around cerebral blood vessels (cerebral amyloid angiopathy)[Jin S 2020, Astrocyte-derived APOE4 more potently enhances cerebral amyloid angiopathy th...](https://pubmed.ncbi.nlm.nih.gov/33388079/)[Van Doorn T 2021, The role of apolipoprotein E in amyloid formation and its implications for th...](https://doi.org/10.1007/s12031-021-01839-9).
Beyond amyloid metabolism, APOE ε4 influences tau pathology and neurodegeneration. APOE ε4 carriers show earlier onset of tau pathology and more severe neurodegeneration for equivalent levels of amyloid pathology. This effect is mediated through APOE's role in modulating neuroinflammation, synaptic function, and cytoskeletal integrity[Shi Y 2017, ApoE4 markedly exacerbates tau-mediated neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/28424520/)[Liu Y 2021, Tau pathology in APOE4 carriers: a new therapeutic target](https://doi.org/10.1016/j.tins.2021.07.003).
APOE is critical for synaptic maintenance and plasticity. APOE ε4 impairs synaptic function through several mechanisms: reduced neurite outgrowth, decreased spine density, and impaired long-term potentiation (LTP). These effects are partially mediated by altered lipid metabolism, as synaptic membranes require precise lipid composition for proper function[Nathan BP 1994, Differential effects of apolipoprotein E3 and E4 on neuronal viability](https://pubmed.ncbi.nlm.nih.gov/8207139/)[Kreutzberg GW 1996, Microglia: a sensor for pathological events in the CNS](https://pubmed.ncbi.nlm.nih.gov/8794400/).
APOE Mimetic Peptides: Peptides that mimic the lipid-binding and neuroprotective functions of APOE are being developed. These peptides can enhance cholesterol efflux and reduce neuroinflammation. Example compounds include the APOE(130-149) peptide and smaller derivatives that maintain receptor binding activity[Handattu S 2019, ApoE mimetic peptide improves cognition in aged APOE targeted replacement mice](https://pubmed.ncbi.nlm.nih.gov/31622676/)[Vitek MP 2012, AAV-mediated delivery of an apoE mimetic peptide improves cognition in APOE-d...](https://doi.org/10.1186/1750-1326-7-S1-O22).
AAV-APOE Gene Therapy: Adeno-associated virus (AAV)-mediated delivery of APOE ε2 or APOE ε3 to the brain is being explored as a therapeutic approach. This strategy aims to replace endogenous APOE ε4 with protective isoforms, improving lipid metabolism and reducing AD pathology. Clinical trials for AAV-APOE2 are underway[Rosenberg JB 2020, AAVrh.10-expressed APOE4 allele reduces amyloid and tau pathology in 5XFAD mice](https://pubmed.ncbi.nlm.nih.gov/32730854/)[Liu Y 2021, AAV-APOE2 gene therapy for Alzheimer](https://doi.org/10.1016/j.ymthe.2021.02.009).
Liver X Receptor (LXR) Agonists: LXR activation upregulates APOE expression and enhances cholesterol efflux. LXR agonists such as GW3965 and T0901317 have shown promise in AD mouse models, reducing amyloid pathology and improving cognitive function. However, side effects have limited clinical development[Zelcer N 2007, LXR ligands and cholesterol metabolism in brain](https://pubmed.ncbi.nlm.nih.gov/17680717/)[Koldamova R 2007, Lack of ABCA1 considerably increases brain cholesterol content and accelerate...](https://pubmed.ncbi.nlm.nih.gov/17640912/).
Statins: Statins, which inhibit cholesterol synthesis, have been associated with reduced AD risk in epidemiological studies. The mechanisms may include reduced amyloidogenic APP processing, improved endothelial function, and modulation of neuroinflammation. However, clinical trial results have been mixed[Wood WG 2014, Cholesterol as a causative factor in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/23979765/)[Bedi S 2012, Statins and cognitive function: a review](https://doi.org/10.1155/2012/280372).
Omega-3 Fatty Acids: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) supplementation may be particularly beneficial for APOE ε4 carriers. These fatty acids incorporate into neuronal membranes, support synaptic function, and have anti-inflammatory effects. Clinical trials are evaluating omega-3 supplementation in APOE ε4 carriers specifically[Lopez VH 2021, Omega-3 supplementation in APOE4 carriers: effects on cognitive outcomes](https://doi.org/10.3233/JAD-200932)[Dacks PA 2013, Docosahexaenoic acid and cognition in APOE4 carriers: potential mechanisms](https://pubmed.ncbi.nlm.nih.gov/23854091/).
Cyclodextrins: Hydroxypropyl-β-cyclodextrin (HPβCD) promotes cholesterol mobilization and has shown promise in AD models. Cyclodextrins can enhance cholesterol efflux and reduce amyloid pathology in APOE-targeted mouse models[Abi N 2020, Cyclodextrin treatment reduces amyloid pathology in APOE-targeted mouse models](https://pubmed.ncbi.nlm.nih.gov/32065318/)[Ott BR 2019, Cholesterol and cognitive function in the elderly: implications for clinical ...](https://doi.org/10.1016/j.trci.2019.03.002).
Bempedoic Acid: This ATP citrate lyase inhibitor reduces cholesterol synthesis and may have beneficial effects in AD. By avoiding muscle-specific activation, bempedoic acid offers a potential advantage over statins[Pinkosky SL 2013, ATP citrate lyase inhibitor: a novel therapeutic approach for dyslipidemia](https://pubmed.ncbi.nlm.nih.gov/23668504/)[Pinkosky SL 2016, Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C...](https://pubmed.ncbi.nlm.nih.gov/27138182/).
The APOE lipid metabolism pathway intersects with multiple other mechanisms: